Clinical Trial

A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase Ib/IIa clinical study of IMC-003 treatment in pulmonary arterial hypertension (PAH) patients receiving background therapy
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-07-23
notable Trial sites reduced: 32 -> 29 locations 2026-07-23
Trial Details
NCT Number NCT07593027
Lead Sponsor ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Conditions Pulmonary Arterial Hypertension PAH
Enrollment 120 participants
Start Date 2026-04-30
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22